» Articles » PMID: 32898786

Participation in Breast Cancer Screening Among Breast Cancer Survivors -A Nationwide Register-based Cohort Study

Overview
Journal Breast
Publisher Elsevier
Specialties Endocrinology
Oncology
Date 2020 Sep 8
PMID 32898786
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to analyse if breast cancer survivors without other breast imaging surveillance attend population-based screening differently than women not previously diagnosed with breast cancer. Further, to analyse if any differences depended on the women's age and years since previous cancer diagnosis. The study was a register-based retrospective cohort study of all women invited to participate in the national breast cancer screening programme in 2015-2016. Participation rates were calculated for breast cancer survivors without breast imaging within 21 months (2-4 years, 4-6 years, 6-10 years and more than 10 years after diagnosis) and for women without previous breast cancer. Relative differences in participation rates between the two groups were calculated. A total of 679,990 women were included in the study (2.6% breast cancer survivors). For breast cancer survivors, participation rates increased with increasing number of years since the previous cancer diagnosis peaking at 80.3% if the cancer diagnosis was more than 10 years ago. For women with no previous breast cancer, participation rate was 80.3%. The relative difference in participation was highest close to the breast cancer diagnosis and for the youngest women participation rates remained lower among breast cancer survivors even more than 10 years after the diagnosis. In conclusion, regardless of age and years since previous breast cancer diagnosis, breast cancer survivors had lower or similar participation rates than women with no previous cancer diagnosis. This indicated that as many as one fifth of the breast cancer survivors are at risk of inadequate surveillance.

Citing Articles

Further insights into the use of contrast-enhanced imaging for breast cancer follow-up: the cons view.

Wallis M Eur Radiol. 2024; .

PMID: 39406958 DOI: 10.1007/s00330-024-11097-5.


Non-participation in breast screening in Denmark: Sociodemographic determinants.

von Euler-Chelpin M, Napolitano G, Lynge E, Borstrom S, Vejborg I BMC Public Health. 2024; 24(1):2024.

PMID: 39075424 PMC: 11285456. DOI: 10.1186/s12889-024-19547-x.


Effects of Apatinib Mesylate Monotherapy on the Incidence of Adverse Reactions and Immune Function in Patients with Breast Cancer after Radical Mastectomy.

Lin S, Zang M Evid Based Complement Alternat Med. 2022; 2022:4022282.

PMID: 35990841 PMC: 9385297. DOI: 10.1155/2022/4022282.

References
1.
Runowicz C, Leach C, Henry N, Henry K, Mackey H, Cowens-Alvarado R . American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2015; 34(6):611-35. DOI: 10.1200/JCO.2015.64.3809. View

2.
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

3.
Gjerstorff M . The Danish Cancer Registry. Scand J Public Health. 2011; 39(7 Suppl):42-5. DOI: 10.1177/1403494810393562. View

4.
Robertson C, Arcot Ragupathy S, Boachie C, Dixon J, Fraser C, Hernandez R . The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation. Health Technol Assess. 2011; 15(34):v-vi, 1-322. PMC: 4781542. DOI: 10.3310/hta15340. View

5.
Schmidt M, Schmidt S, Adelborg K, Sundboll J, Laugesen K, Ehrenstein V . The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019; 11:563-591. PMC: 6634267. DOI: 10.2147/CLEP.S179083. View